IBRX280121C00007500
IBRX Jan 21 2028 7.50 Call
optionOPRA
EODOct 16, 2026
4.20USD-10.638%(-0.50)9,831Vol18,015OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
7.5
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$0.98
IBRX 7.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.47 | -14.83% | 13 | 24 |
| Oct 30, 2026 | 10d | $2.75 | -17.91% | 4 | 94 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | $3.08 | +0.00% | 30 | 30 |
| Jan 15, 2027 | 87d | $2.65 | -11.67% | 315 | 21,039 |
| Jan 21, 2028 | 458d | $4.20 | -10.64% | 9,831 | 18,015 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 3 C | $6.50 | -16.13% | 1 | 31,197 | ITM |
| 3.5 C | $7.10 | +1.87% | 10 | 27,275 | ITM |
| 4 C | $6.75 | -1.75% | 15 | 2,170 | ITM |
| 4.5 C | $6.65 | +2.78% | 2 | 380 | ITM |
| 5 C | $5.44 | -11.54% | 4,002 | 12,523 | ITM |
| 5.5 C | $5.21 | -12.14% | 2 | 3,508 | ITM |
| 7.5 C | $4.20 | -10.64% | 9,831 | 18,015 | ITM |
| 10 C | $3.20 | -14.44% | 677 | 10,691 | OTM |
| 12 C | $2.70 | -20.59% | 16 | 1,740 | OTM |
| 15 C | $2.80 | +3.70% | 53 | 7,866 | OTM |
| 17 C | $2.82 | +4.44% | 30 | 1,006 | OTM |
| 20 C | $1.50 | -23.08% | 46 | 1,671 | OTM |
| 22 C | $1.30 | -18.75% | 185 | 8,022 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.